Herbert Virgin - 07 Sep 2021 Form 4 Insider Report for Vir Biotechnology, Inc. (VIR)

Role
EVP, Research & CSO
Signature
/s/ Howard Horn, Attorney-in-Fact
Issuer symbol
VIR
Transactions as of
07 Sep 2021
Net transactions value
-$198,564
Form type
4
Filing time
09 Sep 2021, 16:59:58 UTC
Previous filing
26 Aug 2021
Next filing
22 Sep 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VIR Common Stock Options Exercise $6,311 +4,125 +4.1% $1.53* 103,825 07 Sep 2021 Direct
transaction VIR Common Stock Sale $67,375 -1,375 -1.3% $49.00 102,450 07 Sep 2021 Direct F1
transaction VIR Common Stock Sale $137,500 -2,750 -2.7% $50.00 99,700 07 Sep 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VIR Stock Option (Right to Buy) Options Exercise $0 -4,125 -1.5% $0.000000 263,255 07 Sep 2021 Common Stock 4,125 $1.53 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 26, 2021.
F2 1/4 of the shares subject to the stock option vested and became exercisable on January 8, 2019, and the remaining shares vest in 36 equal monthly installments thereafter.